Early diagnosis and treatment of Alzheimer’s disease could save millions or even billions of dollars while simultaneously improving care, according to new work by University of Wisconsin-Madison researchers.
Patients with Alzheimer’s disease and other dementias are heavy users of long-term care services, especially nursing home care, with estimated annual costs upward of tens of billions of dollars nationwide.
Much of the fiscal burden is borne by state and federal governments — and thus taxpayers — through the Medicaid and Medicare programs.
For example, the Wisconsin Medicaid program spends almost half a billion dollars each year on nursing home care for just 11,000 dementia patients — a tiny fraction of the estimated 160,000 affected people in the state, says Mark Sager, director of the Wisconsin Alzheimer’s Institute of the UW-Madison School of Medicine and Public Health.
These costs could be greatly reduced by earlier diagnosis and treatment, he says in a new study co-authored by La Follette School of Public Affairs professor David Weimer.
The research, a cost-benefit analysis of the social and fiscal impacts of early identification and treatment of Alzheimer’s disease, using Wisconsin as a model, appears in the May issue of Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association.
“The future of this disease is to intervene decades before someone becomes symptomatic.
This analysis says you can save literally billions of dollars in long-term care costs if you can intervene at an earlier stage,” Sager says. “What you don’t know costs a lot of money when it comes to this disease.”
The issue is becoming more pressing as the population ages, with some estimates placing the incidence of Alzheimer’s disease in the U.S. around 1 million cases by 2050, the authors say.
“We need to begin now to make the public-policy changes that will allow and encourage early recognition and intervention,” says Sager.
“This article says to all the legislators facing deficits, ‘here’s a way to save money, and you can do it by providing better care.’ It’s a win for legislators, it’s a win for patients, it’s a win for families.”
The analysis considers two types of interventions following diagnosis: patient drug treatment and caregiver-support programs. Each would provide positive net savings, with the greatest benefits achieved using a combination of both.
“Even just with currently available drug treatments, [early diagnosis] seems to offer positive social benefits. If we had a stronger caregiver-support network, it could be even greater,” Weimer says.
They predict even larger benefits if more effective drug treatments are developed and if public policy supported caregiver benefits, such as counseling and support groups.
Currently, Medicare does not support caregiver-intervention programs. Even accounting for implementation costs, the new analysis suggests that they would result in net savings to governments by reducing the care burden on medical systems.
“It does take some investment early on, and of course this is a time when all state dollars are tight. But from the long-run perspective, it looks like it’s a clear winner,” says Weimer.
In addition to substantial financial savings — on average $10,000 net savings to the state alone per patient diagnosed in Wisconsin — their analysis showed that early identification and intervention would lead to positive social outcomes, including slower disease progression and improved quality of life for the patients’ families and caregivers.
These combined social benefits would total around $100,000 for the typical patient, Weimer says, and could climb to five times that with the development of drugs that could stop disease progression.
A major challenge to reaping these potential savings is the current lack of mechanisms for screening and early diagnosis, allowing the vast majority of affected people to go unrecognized, Sager says.
“We will have to develop systems of cognitive screening if we are going to eventually identify people at early stages when future medications and caregiver interventions are most likely to be helpful.”
“There are many physical, emotional and social benefits of early detection, diagnosis and intervention for people with Alzheimer’s and their caregivers,” says Shelley Morrison Bluethmann, director of early stage initiatives at the Alzheimer’s Association, a health advocacy organization.
“Early detection empowers people with the disease to participate in decisions about their treatment and future care, as well as consider clinical trial opportunities. Being diagnosed early is vital to receiving the best help and care possible.”
The work was partially supported by the Institute for Clinical and Translational Research at UW-Madison.
Source: University of Wisconsin-Madison
Alzheimer Progressive and Degenerative Disease Of the Brain
It is a disease that attacks the brain and causes problems of memory, thought and conduct. This disease gets worse with time. In his first stage, the people express frustrations by the difficulty to formulate and to express their thoughts.
Others of the first symptoms are: the lost one of the memory that affects the abilities in the work; difficulty in the execution of daily tasks, difficulty in the learning of new tasks; lost of the sense of the time and problems with the language.
Alzheimer Is a disease that attacks the brain is progressive and degenerative cause problems of memory, thought and conduct. It affects in the attention, decision making, judgment, language and personality.
This disease gets worse with time. In addition to the disease of Alzheimer, there are other types of dementia, including vascular dementia (cerebral paralysis), dementia with bodies of Lewy, disease of Pick and others. Different types from dementia require different treatments.
Causes, Incidence And Factors Of Risk:
The cause of the disease of Alzheimer is not known, but it is not part of the process of normal aging. The previous theories have discarded on the accumulation of aluminum, lead, mercury and other substances in the organism.
The diagnosis of the disease of Alzheimer is made on the base in the symptoms characteristic of the disease and after excluding other possible causes from dementia.
It can be confirmed with microscopic studies of a cerebral weave sample after the death. The cerebral weave naked sample “neurofibrilares” (coiled protein fragments within the neurons that obstructs them), aneuritic plates” (abnormal agglomerations of nervous cells died and that is dying, other cerebral cells and protein) and “senile plates” (areas where accumulated products of neurons died around proteins are had).
Although these changes happen in certain degree in all the brains with the age, appear many more in the brains of the people with disease of Alzheimer.
The destruction of the nervous cells (neurons) takes to a diminution of the neurotransmitters (substances secreted by a neuron to send the messages to another neuron), whose correct balance is critical for the brain.
The three neurotransmitters commonly affected by the disease of Alzheimer are acetylcholine, serotonin and Norepinefrina; the acetylcholine is affected.
The disease of Alzheimer has a gradual progress. In his first stage, the people express frustrations by the difficulty to formulate and to express their thoughts.
Others of the first symptoms are: the lost one of the memory that affects the abilities in the work; difficulty in the execution of daily tasks (such as the balance of the book of accounts or to prepare the food); difficulty in the learning of new tasks; lost of the sense of the time and problems with the language.
As the disease progresses, a person with the disease or some related disorder, can experience problems with the direction sense, poor man or diminution of the judgment, problems with the abstract thought, problems with the location of the objects, changes in the behavior, changes in the personality and loss of the initiative.
These severe changes interfere in daily the labor and social activities. The seconds affected by the disease are the members of the family that help the people who suffer of Alzheimer.
These can experience emotional stress, blames, familiar fatigue, fury, isolation, conflicts, anxiety and depression.
At the moment there is no an only clinical examination to identify the disease of Alzheimer, although this is an area in which intense studies are made.
Before diagnosing the disease other conditions must be excluded, which can be potentially reversible. One is not due to assume that a person has the disease of Alzheimer. T
he person must be examined completely, which includes physical examinations, neurological, psychological and psychiatric, as well as laboratory studies.
This entailed to I diagnose enough precise. The only way to confirm I diagnose of the disease is examinee woven cerebral with a microscope, which single can become when a autopsy is made.
Treatment With Medicines:
Medicine table Moderate of the Disease Alzheimer
Four of these medicines are called “inhibitors of colinesterasa.” They are prescribed for the treatment of the symptoms of slight degree to moderate of the disease of Alzheimer.
These medicines can help to delay the symptoms or to prevent that they get worse by a limited time and can help to control some symptoms of behavior. The medicines are: Reminyl® (galantamina), Exelon® (rivastig-mine), Aricept® (donepezilo), Cognex® (tacrina).
There is no published study that compares these medicines directly. Since the four work of a similar way, it does not hope that the change of one from these medicines to another one produces significantly different results.
Nevertheless, a person who suffers of the disease of Alzheimer can respond better to a medicine than to another one. Cognex® (tacrina) no longer is commercialized actively by the manufacturer. One thinks that it is possible to be dealt to these people with antidepressants and one of medicines, like donepezil, at the present time used for the Disease of Alzheimer.
The antidepressants known like reabsorbing inhibitors of selective serotonin (SSRI, pos abbreviations in English) can be particularly effective in alleviating the depression, irritability and the excitation associated with the Disease of Alzheimer. These symptoms and the most severe symptoms, including verbal or physically aggressive behavior and rambling, have traditionally dealt with antipsychotics medicines like haloperidol (Haldol) and the antidepressant desyrel (Trazodone).
The disease of Alzheimer is a chronic upheaval neuro degenerative; of heterogeneous etiology and clinical presentation that has become a gigantic problem of health in the last fifty years.
Nevertheless, most of the experts they agree in which most of the patients never they are not diagnosed, and only one minimum fraction receives the suitable treatment, although the investigations in the etiology and the pharmacotherapy of the disease have provided us therapeutic and preventive strategies that improve the symptoms and reduce the risk of suffering the disease.